Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates

Cocrystal Pharma, Inc.

2025-Q3 EPS reported -$0.61

Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
Granted NIH SBIR award of $500,000 for influenza A/B replication inhibitor program.
Q3 2025 R&D expenses $954,000 vs $3.2M in Q3 2024; net loss $2.0M ($0.19 per share) vs $4.9M ($0.49 per share) year-over-year.
Raised $4.7M in registered direct offering in September 2025 and $1.03M in private placement in October 2025.
CC-42344 Phase 2a study completed; showed favorable safety, no SAEs; efficacy not reported due to trial conduct issues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.